AstraZeneca』s Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukaemia Trials
Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: 「These data add to the growing body of evidence that supports the potential of&nb......
